InDevR licenses Mount Sinai influenza antibodies for VaxArray neuraminidase potency assay

VaxArray technology advances toward tracking neuraminidase levels in flu vaccines through an exclusive, worldwide antibody license agreement with the Icahn School of Medicine at Mount Sinai.

InDevR, a Boulder-based progressive analytical technology and life science instrumentation company today announced that it has entered into an exclusive, world-wide license agreement for monoclonal antibodies developed by scientists at the Icahn School of Medicine at Mount Sinai. The license agreement with Mount Sinai will provide InDevR with a unique set of anti-neuraminidase monoclonal antibodies for rapid, subtype specific quantification of neuraminidase in the multiplexed VaxArray system.

As the maker of the VaxArray Vaccine Potency platform, InDevR is focused on providing vaccine manufacturers with streamlined and cost efficient tools to modernize vaccine production. The commercially available VaxArray Influenza Seasonal Hemagglutinin Kit for seasonal influenza vaccine potency is used for quantification of hemagglutinin within influenza vaccines. InDevR also has a strong product development pipeline that includes VaxArray reagent kits for pandemic hemagglutinin and flu neuraminidase.

According to Dr. Kathy Rowlen, InDevR’s CEO, “There is growing scientific evidence that neuraminidase plays an important role in the immune response to flu vaccines. However, the levels of neuraminidase in flu vaccines are not currently regulated, in part because there are no commercially available reagent kits for quantification. Our goal is to create a reliable ready-to-use assay that will ultimately enable the flu vaccine industry as a whole to better understand how neuraminidase levels impact flu vaccine efficacy. This license for the superb antibodies developed at Mount Sinai will help us achieve that goal.”

“We’re thrilled to enter into a partnership with InDevR to advance this Mount Sinai technology into the flu vaccine ecosystem. This invention reflects the efforts of talented scientists here at Mount Sinai who combine their expertise in life sciences with their drive for innovation and translation of commercially-relevant research,” said Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners.

About InDevR

InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. In addition to the VaxArray® Vaccine Potency system, InDevR also developed and markets Cypher One™ Automated Hemagglutination Analyzer for use in hemagglutination and hemagglutination inhibition assays. For more information about the company and products, please visit https://www.indevr.com or call 303-402-9100.

About Mount Sinai Innovation Partner (MSIP)

MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into healthcare products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and non-profit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, visit http://www.ip.mountsinai.org.